Idera Pharmaceuticals, Inc.
(NASDAQ : IDRA)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
Loading IDRA News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
0.97%73.430.9%$725.96m
AMGNAmgen Inc.
0.73%180.481.1%$595.28m
CELGCelgene Corporation
1.49%137.011.1%$590.43m
REGNRegeneron Pharmaceuticals, Inc.
2.75%520.742.7%$544.96m
BIIBBiogen Inc.
0.71%283.941.2%$408.30m
VRTXVertex Pharmaceuticals Incorporated
-0.19%159.381.9%$369.41m
ALXNAlexion Pharmaceuticals, Inc.
1.79%129.581.9%$285.60m
CLVSClovis Oncology, Inc.
4.03%87.2318.0%$175.92m
INCYIncyte Corporation
2.07%133.152.6%$169.94m
TSROTESARO, Inc.
3.18%127.9614.7%$169.45m
ILMNIllumina, Inc.
-0.49%173.033.5%$159.06m
EXELExelixis, Inc.
1.94%27.276.5%$156.33m
BMRNBioMarin Pharmaceutical Inc.
0.63%87.784.4%$131.88m
KITEKite Pharma, Inc.
2.87%108.4616.1%$123.07m
BLUEBluebird Bio, Inc.
0.72%98.0019.3%$118.15m

Company Profile

Idera Pharmaceuticals, Inc. is a clinical stage biotechnology company, which is engaged in discovery, development and commercialization of novel oligonucleotide therapeutics for oncology and rare diseases. The company uses two distinct proprietary drug discovery technology platforms to design and develop drug candidates: Toll-like receptor targeting technology and third-generation antisense technology. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Cambridge, MA.